Amylyx Advances AMX0114 to Second Cohort Enrollment After Positive Phase 1 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Newsfilter
- Positive Safety Profile: In the first cohort of the LUMINA trial, all 12 participants exhibited no treatment-related serious adverse events, indicating a favorable safety profile for AMX0114, which supports the progression to the second cohort.
- Accelerated Enrollment: Amylyx plans to initiate enrollment for the second cohort in Canada later this month and in the U.S. in January, aiming to expedite research into potential treatments for ALS, a disease with significant unmet needs.
- Biomarker Insights: The LUMINA trial will assess the impact of AMX0114 on neurofilament light chain (NfL) levels, with biomarker data from the first cohort expected in the first half of 2026, potentially offering new insights into ALS treatment.
- Clinical Trial Framework: This trial is designed as a multicenter, randomized, double-blind, placebo-controlled study, intending to recruit approximately 48 adult participants to further validate the safety and efficacy of AMX0114.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like AMLX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on AMLX
Wall Street analysts forecast AMLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMLX is 20.14 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.505
Low
15.00
Averages
20.14
High
25.00
Current: 14.505
Low
15.00
Averages
20.14
High
25.00
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Amylyx Pharmaceuticals' Corporate Governance Breaches
- Shareholder Action: Halper Sadeh LLC is investigating whether certain officers and directors of Amylyx Pharmaceuticals breached their fiduciary duties, potentially leading to shareholder losses.
- Legal Relief Options: Long-term shareholders of Amylyx may seek corporate governance reforms, fund recovery, or court-approved financial awards, enhancing shareholder rights and protections.
- Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby increasing transparency and accountability, which ultimately helps enhance shareholder value.
- Law Firm Background: Halper Sadeh LLC represents global investors focusing on securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors in the past.
Continue Reading
AMLX Options Contract Analysis and Investment Opportunities
- Put Option Appeal: The current bid for the $15.00 put option is $3.20, and if an investor sells this contract, they commit to buying the stock at $15.00, resulting in an effective cost basis of $11.80, which offers an attractive 4% discount compared to the current price of $15.55, appealing to those interested in AMLX shares.
- Yield Potential Analysis: Should the put option expire worthless, it would yield a 21.33% return on the cash commitment, or an annualized return of 33.28%, showcasing the YieldBoost potential of this strategy, which is likely to attract yield-seeking investors.
- Call Option Opportunity: The $16.00 call option has a current bid of $3.60, and if an investor buys AMLX shares at $15.55 and sells this call, they could achieve a total return of 26.05% if the stock is called away at expiration, highlighting the attractiveness of this strategy.
- Risk and Return Assessment: The $16.00 call option has a 32% chance of expiring worthless, in which case the investor retains both the shares and the premium collected, providing an additional 23.15% return, or an annualized yield of 36.12%, further enhancing investor return expectations.
Continue Reading